Director Appointment

RNS Number : 4155Q

Iconic Labs PLC

20 February 2023

 

20 February 2023

Iconic Labs PLC

("Iconic" or the "Company")

Director Appointment

Iconic Labs PLC (LSE:ICON), is pleased to announce that Emmanuel Blouin has been appointed to the Board of Directors with immediate effect.

Mr. Blouin has 25 years of investment and banking experience. He was a senior banker with Morgan Stanley, JP Morgan and BNP Paribas, during which he was involved in over €50 billion of capital markets, corporate finance and property transactions across Europe. In 2008, Mr. Blouin established Esterel Capital, a London-based boutique focusing on real estate and finance, where he continues to be Managing Partner.

Mr. Blouin is also currently a director of Courbet SA, a hospitality investment company listed on the Paris Stock Exchange, as well as an Independent Non-Executive Director of Aradei Capital, a commercial property investment and management company listed on the Casablanca Stock Exchange.

The following information is disclosed about Mr. Emmanuel Blouin:

Current Directorships / Partnerships

Aradei Capital

Courbet SA

Esterel Capital LLP

Stanrock Capital Ltd

Squareconcept Property Management Ltd

Previous Directorships / Partnerships held in the past 5 years: None

Brad Taylor, CEO of Iconic Labs, commented:

"I welcome Emmanuel to the Iconic board of directors. He is a highly skilled professional with significant expertise in corporate finance and international dealmaking. This experience, coupled with his vast network, will serve Iconic and its shareholders well as the company develops and implements an acquisition and growth strategy. With Iconic directors now in the United States, United Kingdom, and Europe, we are well-positioned to maximize our potential for value creation." 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

- ENDS -

For any further information or enquiries please contact:

[e-mail]

 

END

 

 

BOADBLBLXLLZBBK